ACB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AC

Mkt Cap

$252.7M

Volume

957.42K

Next Earnings

November 4th

Loading chart

AC

ACBAurora Cannabis Inc. Common Shares

ACB

Pay with—

Available Balance0.00

AC

Mkt Cap

$252.6M

Volume

957.42K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

3 Huge Red Flags From Tilray's Q1 Earnings ReportTilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.The Motley Fool · Oct 12, 2026

Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.Curaleaf launched a hostile takeover bid for Aurora Cannabis at $4 per share in August 2026, which Aurora rejected as undervalued. The situation has escalated with Curaleaf attempting to block Aurora's ability to raise capital through stock sales. With the tender offer open until December 1, significant animosity between the companies makes integration difficult if the acquisition succeeds, while Aurora shareholders face uncertainty about whether to accept the offer or hold for potential higher valuations.The Motley Fool · Sep 26, 2026

Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky StockTilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.The Motley Fool · Sep 15, 2026

Should You Buy Canopy Growth Stock on the Rebound?Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.The Motley Fool · Sep 5, 2026

Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?Curaleaf has launched a hostile takeover bid for Aurora Cannabis at $4 per share, which Aurora's board has rejected. While Aurora has transformed into a leaner, profitable medical cannabis company with strong international operations and a solid balance sheet, investors shouldn't buy the stock purely as a takeover bet. The company's genuine turnaround in medical cannabis and European expansion could make Curaleaf's offer undervalued, but there's no guarantee the deal will close or be increased.The Motley Fool · Aug 28, 2026

The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.Curaleaf initiated a takeover bid for Aurora Cannabis, signaling an M&A wave in the cannabis sector following expected federal rescheduling from Schedule I to Schedule III. Green Thumb Industries, a profitable multi-state operator, has the financial capacity to pursue acquisitions but is likely to favor disciplined, smaller bolt-on deals in limited-license states over aggressive megamergers, prioritizing share buybacks and organic growth.The Motley Fool · Aug 23, 2026

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.The cannabis sector is undergoing consolidation as weaker players exit and stronger companies acquire competitors. Curaleaf has made an unsolicited $4 per share bid for Aurora Cannabis. The article identifies Canopy Growth and Tilray Brands as the biggest potential winners in this consolidation trend, with Canopy benefiting from its balance sheet reset and Tilray diversifying beyond marijuana into alcohol and consumer brands.The Motley Fool · Aug 21, 2026

Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?Curaleaf formally launched a hostile takeover bid for Aurora Cannabis on August 18, 2026, offering $4 per share (45% premium) with potential to reach $5 per share. The analyst recommends passing on Curaleaf stock, citing regulatory mismatches between U.S. and Canadian markets, complicated international distribution networks, and neither company's proven profitability track record. Aurora shares trade at a discount to the offer price, suggesting investor skepticism about deal completion.The Motley Fool · Aug 20, 2026

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?Curaleaf launched an unsolicited $272 million bid to acquire Aurora Cannabis at $4 per share, signaling renewed consolidation in the cannabis industry. The move raises questions about whether Canopy Growth could become the next acquisition target. While Canopy has valuable global medical cannabis assets and established brands, its complex corporate structure and ongoing turnaround make it a less obvious fit for potential acquirers.The Motley Fool · Aug 16, 2026

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.Curaleaf launched a hostile takeover bid for Aurora Cannabis at $4 per share (45% premium), comprising 0.34 Curaleaf shares plus $0.75 cash, with a $5 per share cap. Aurora's board will consider the offer but criticized the financing details and price cap. The combination appeals due to Aurora's strong medical marijuana business with higher margins, though hostile bids have historically struggled.The Motley Fool · Aug 12, 2026

to start trading

AC

ACBAurora Cannabis Inc. Common Shares

ACB

Pay with—

Available Balance0.00

Your PositionYou don't own any ACB yet.

Related Tickers

Earnings